Company profile
BioXcel Therapeutics, Inc. CIK 1720893
Tickers
BTAI (Nasdaq) · BTAIQ (OTC)
Industry
Pharmaceutical Preparations
Headquarters
New Haven, CT 06511
Fiscal year end
2025 (FY)
Key Financials
Revenue
$642.0K
Net income
-$69.90M
Total assets
$44.92M
Total liabilities
$140.38M
Stockholders' equity
-$95.46M
Cash & equivalents
$28.42M
Operating income
-$50.46M
Operating cash flow
-$57.62M
Capital expenditures
$0
Fiscal year 2025, via 10-K filed 2026-03-27. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
-7,860.0%
Net margin
-10,887.4%
Free cash flow
-$57.62M
Free cash flow margin
-8,974.3%
Liabilities / assets
312.5%
Equity / assets
-212.5%
CapEx / revenue
0.0%
Operating cash flow / net income
0.82×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
$642.0K
-$69.90M
$44.92M
$140.38M
-$95.46M
2024
$2.27M
-$59.60M
$38.34M
$131.44M
-$93.10M
2023
$1.38M
-$179.05M
$73.70M
$130.21M
-$56.51M
2022
$375.0K
-$165.76M
$205.85M
$129.08M
$76.78M
2021
—
-$106.93M
$239.44M
$17.77M
$221.67M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 8-K
2026-09-01
Financials filed via
Form 10-K
filed 2026-03-27
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
New Haven, CT 06511
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:22 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.